- Home
- EVLV vs VRDN Comparison
EVLV vs VRDN Comparison
Compare EVLV & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVLV
- VRDN
- Stock Information
- Founded
- EVLV 2013
- VRDN 2006
- Country
- EVLV United States
- VRDN United States
- Employees
- EVLV N/A
- VRDN N/A
- Industry
- EVLV Computer peripheral equipment
- VRDN Medical Specialities
- Sector
- EVLV Technology
- VRDN Health Care
- Exchange
- EVLV Nasdaq
- VRDN Nasdaq
- Market Cap
- EVLV 1.4B
- VRDN 1.6B
- IPO Year
- EVLV N/A
- VRDN N/A
- Fundamental
- Price
- EVLV $8.28
- VRDN $22.15
- Analyst Decision
- EVLV Strong Buy
- VRDN Strong Buy
- Analyst Count
- EVLV 4
- VRDN 10
- Target Price
- EVLV $8.88
- VRDN $36.78
- AVG Volume (30 Days)
- EVLV 2.5M
- VRDN 1.3M
- Earning Date
- EVLV 11-13-2025
- VRDN 11-11-2025
- Dividend Yield
- EVLV N/A
- VRDN N/A
- EPS Growth
- EVLV N/A
- VRDN N/A
- EPS
- EVLV N/A
- VRDN N/A
- Revenue
- EVLV $121,011,000.00
- VRDN $305,000.00
- Revenue This Year
- EVLV $31.07
- VRDN N/A
- Revenue Next Year
- EVLV $17.67
- VRDN $34,044.63
- P/E Ratio
- EVLV N/A
- VRDN N/A
- Revenue Growth
- EVLV 36.64
- VRDN 5.90
- 52 Week Low
- EVLV $2.04
- VRDN $9.90
- 52 Week High
- EVLV $8.91
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- EVLV 56.91
- VRDN 55.11
- Support Level
- EVLV $7.61
- VRDN $20.71
- Resistance Level
- EVLV $8.31
- VRDN $25.00
- Average True Range (ATR)
- EVLV 0.43
- VRDN 1.11
- MACD
- EVLV 0.00
- VRDN -0.08
- Stochastic Oscillator
- EVLV 64.51
- VRDN 35.90
About EVLV Evolv Technologies Holdings Inc.
Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).